- Home
- / Orthocell
Orthocell
Stock Price
$0.5
2024-10-04
Market Capitalization
$96.4 M
2024-10-04
Revenue
$7.6 M
FY, 2025
Orthocell Summary
Company Summary
- Overview
- Orthocell is a company that develops devices for regenerating mobility of tendon, cartilage, and soft tissue. Its products include Ortho-ATI (Autologous Tenocyte Implantation) and Ortho-ACI (Autologous Chondrocyte Implantation) for treatment of chronic tendon and cartilage injuries. The company also offers CelGro, a collagen medical device for tissue repair.
- Type
- Public
- Status
- Active
- Founded
- 2006
- HQ
- Murdoch, AU | view all locations
- Cybersecurity rating
Table of Contents
Key People
Matt Callahan, Director
M.h. Zheng, Chief Scientific Officer
Lars Lidgren, Director
LocationsView all
1 location detected
Murdoch, WA HQ
Australia
South St
Orthocell Financials
Summary Financials
- Revenue (H1, 2026)
- $5.4M
- Gross profit (H1, 2026)
- $8.0M
- Net income (H1, 2026)
- ($5.2M)
- Cash (H1, 2026)
- $7.4M
- EBIT (H1, 2026)
- ($5.8M)
Footer menu
Product
- Intelligence Suite
- Supplier Intelligence Platform
- Craft Intelligence Portal
- Craft API
- Craft for Teams
- Supplier Intelligence Platform
- Craft Alerts
- Craft N-Tier Mapping
- Craft Risk Hub
- Chrome extension
Resources
© Craft.co 2026